Should a triglyceride level of 186 mg/dL be treated in a patient who is already at goal for LDL‑C and non‑HDL‑C while on statin therapy?

Management of Triglyceride Level of 186 mg/dL in a Patient at LDL-C Goal on Statin Therapy

For a triglyceride level of 186 mg/dL in a patient already at LDL-C and non-HDL-C goals on statin therapy, initiate therapeutic lifestyle changes as the primary intervention, and consider intensifying statin therapy or adding niacin/fibrate if non-HDL-C remains elevated. 1

Risk Stratification and Treatment Thresholds

Your patient's triglyceride level of 186 mg/dL falls into the 150-199 mg/dL category, which represents borderline-high triglycerides. The critical next step is to calculate non-HDL-C (total cholesterol minus HDL-C), as this becomes the secondary treatment target when triglycerides are ≥150 mg/dL. 1

For Patients with Established ASCVD or Very High Risk:

• If non-HDL-C is ≥130 mg/dL: Intensify therapy with higher-dose statin or add niacin/fibrate 1
• If non-HDL-C is ≥100 mg/dL in very high-risk patients: Consider additional therapy as this represents a reasonable target 1
• The presence of triglycerides 200-499 mg/dL mandates treating non-HDL-C to <130 mg/dL 1

For Primary Prevention Patients:

• If triglycerides are 150-199 mg/dL: Therapeutic lifestyle changes are the primary recommendation 1
• Drug therapy is generally reserved for triglycerides ≥200 mg/dL in this population 1

Therapeutic Lifestyle Changes (First-Line for 150-199 mg/dL)

All patients with triglycerides 150-199 mg/dL should receive intensive lifestyle modification before considering additional pharmacotherapy. 1

Dietary Modifications:

• Reduce saturated fat to <7% of total calories 1
• Limit cholesterol intake to <200 mg/day 1
• Reduce trans fatty acids to <1% of total calories 1
• Limit alcohol consumption (2 drinks/day in men, 1 drink/day in women) 1
• Referral to a registered dietitian nutritionist is strongly recommended 1

Physical Activity and Weight Management:

• Encourage 30-60 minutes of moderate-intensity aerobic activity at least 5 days per week (preferably daily) 1
• Target BMI 18.5-24.9 kg/m² 1
• For waist circumference ≥35 inches (women) or ≥40 inches (men), initiate weight management strategies 1

Pharmacologic Intensification

When to Consider Additional Therapy:

If triglycerides remain 200-499 mg/dL after lifestyle changes, or if non-HDL-C is not at goal, consider the following options: 1

1. Intensify statin therapy to higher doses (Class I recommendation for triglycerides 200-499 mg/dL) 1
2. Add niacin (Class IIa recommendation after LDL-C lowering therapy) 1
3. Add fibrate therapy (Class IIa recommendation after LDL-C lowering therapy) 1

Important Caveats:

The combination of high-dose statin plus fibrate increases the risk of severe myopathy; statin doses should be kept relatively low with this combination. 1

For triglycerides ≥500 mg/dL, fibrate or niacin therapy is indicated before LDL-lowering therapy to prevent acute pancreatitis (Class I recommendation). 1

Evidence for On-Treatment Triglyceride Levels

Emerging evidence suggests that on-treatment triglyceride levels matter for cardiovascular outcomes. In statin-treated patients with acute coronary syndrome, on-treatment triglyceride levels ≥150 mg/dL were independently associated with higher risk of recurrent coronary events compared to levels <150 mg/dL (HR 0.80,95% CI 0.66-0.97, p=0.025). 1, 2

High on-treatment triglyceride levels (≥150 mg/dL) were an independent predictor for major adverse cardiac events (HR 4.01,95% CI 1.85-9.06, p=0.001) in patients following percutaneous coronary intervention, even when baseline triglyceride levels were not predictive. 2

Non-HDL-C as the Key Target

Non-HDL-C has emerged as a better risk predictor than LDL-C alone and represents the cholesterol content of all atherogenic apolipoprotein B-containing lipoproteins. 3

For patients with triglycerides ≥200 mg/dL, non-HDL-C should be <130 mg/dL (Class I recommendation). 1

For very high-risk patients with triglycerides ≥200 mg/dL, a non-HDL-C goal of <100 mg/dL is reasonable (Class IIa recommendation). 1

Clinical Algorithm

1. Calculate non-HDL-C (total cholesterol - HDL-C) 1
2. Assess cardiovascular risk category (primary prevention vs. established ASCVD) 1
3. Initiate or intensify therapeutic lifestyle changes 1
4. If non-HDL-C is above goal after 12 weeks of lifestyle changes:
   • Consider higher-dose statin 1
   • Consider adding niacin or fibrate (with caution regarding statin-fibrate combination) 1
5. Reassess lipid panel in 4-12 weeks after any therapeutic change 1